首页> 美国卫生研究院文献>BioMedicine >Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review
【2h】

Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review

机译:携带90Y的微球治疗肝细胞癌的研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatocellular carcinoma (HCC) is a disease usually diagnosed in its advanced-stage, and is frequently not amenable to curative surgical treatment. Also, HCC is resistant to chemotherapy and less vulnerable to radiation therapy compared to normal hepatic parenchyma. Both of these facts render the efficacy of adjuvant and palliative treatments problematic. Selective internal radiation therapy (SIRT) with 90Y-bearing microspheres is characterized by preferentially delivering substantially high doses of radiation to a liver tumor dose simultaneously limiting the damage to its non-tumorous cells, providing an opportunity for effective local tumor control and even tumor regression therapy. The current article reviews the specific characters, dosimetry, possible applications, and special considerations toward the pre-existing radiation therapy of 90Y microsphere SIRT in treating HCC.
机译:肝细胞癌(HCC)是通常在晚期阶段诊断的疾病,通常不适合治愈性外科治疗。而且,与正常的肝实质相比,HCC对化学疗法具有抗药性,并且对放射疗法的抵抗力较小。这两个事实都使得辅助治疗和姑息治疗的功效成问题。带有 90 Y的微球的选择性内部放射疗法(SIRT)的特点是优先向肝脏肿瘤剂量提供高剂量的辐射,同时限制了其对非肿瘤细胞的损害,为有效的局部肿瘤控制,甚至肿瘤消退治疗。本文综述了 90 Y微球SIRT治疗HCC的具体特征,剂量学,可能的应用和特殊考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号